Document is current
Any future updates will be listed below
-
Authors
Liguoro, Domenico
Frigerio, Rachele
Ortolano, Arianna
Sacconi, Andrea
Acunzo, Mario https://orcid.org/0000-0002-3942-9061
Romano, Giulia
Nigita, Giovanni https://orcid.org/0000-0001-8880-4334
Bellei, Barbara https://orcid.org/0000-0002-3883-5500
Madonna, Gabriele https://orcid.org/0000-0001-9395-3190
Capone, Mariaelena https://orcid.org/0000-0002-1352-2532
Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
Mancini, Rita https://orcid.org/0000-0002-5491-2449
Ciliberto, Gennaro https://orcid.org/0000-0003-2851-8605
Fattore, Luigi
- License Information
-
More Information
Article History
Received: 7 September 2023
Revised: 27 February 2024
Accepted: 29 February 2024
First Online: 12 March 2024
Competing interests
: All the authors declare no competing interests with the exception of P.A.A. He has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. Travel support by Pfizer. The funders of this study had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
: The use of human samples was approved by Istituto Pascale’s Ethical Committee with the protocol DSC/2893 on April 11, 2015. All patients signed a general informed consent, which allowed the use of this material for research purposes and analyzed in an anonymous manner.
